Dartmouth-Hitchcock Medical Center
The purpose of this study is to learn if certain drug combinations are effective treatments for patients with advanced ER+/HER2- who have previously been treated with palbociclib, ribociclib, or abemaciclib.
Inclusion Criteria: 1. Post-menopausal women ≥18 years of age with metastatic ER+ breast cancer, or with locally recurrent ER+ disease not amenable to therapy for curative intent. 2. Patient must be post-menopausal per NCCN guidelines. 3. Patient must have been treated with a CDK4/6i (either palbobclib, ribociclib, or abemaciclib) alone or in combination with an endocrine agent in the advanced disease setting. * Up to 3 lines of therapy following CDK4/6i are permissible. * Any number of prior lines of endocrine-containing therapy is permissible. * Up to 1 prior line of chemotherapy…
Fulvestrant will be administered intramuscularly into the buttocks in combination with one of the other interventions as outlined above.
Neratinib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
Alpelisib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
Everolimus will be administered orally in tablet form once daily in combination with fulvestrant administration as outlined above.
Abemaciclib will be administered orally in tablet form twice daily in combination with fulvestrant administration as outlined above.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.